Juno gets some bad­ly need­ed re­lief af­ter a glimpse of up­beat ear­ly da­ta on JCAR017

Anx­ious to turn the page on a dead­ly se­ries of cere­bral ede­ma cas­es, Juno Ther­a­peu­tics to­day turned to an up­beat set of pre­lim­i­nary da­ta for JCAR017, which may soon emerge as its top drug in the pipeline.

Twelve of 20 pa­tients who could be eval­u­at­ed for ef­fi­ca­cy in the study of CD19-pos­i­tive cas­es of non-Hodgkin lym­phoma demon­strat­ed a com­plete re­sponse to the CAR-T ther­a­py fol­low­ing treat­ment at dose lev­el 1 (5×107 cells). There was some ev­i­dence of dura­bil­i­ty, with 42% of the pa­tients (8/19) with dif­fuse large B-cell lym­phoma treat­ed more than three months be­fore the da­ta cut­off ex­pe­ri­enc­ing an on­go­ing re­sponse. And there were no cas­es of se­vere cy­tokine re­lease syn­drome with grade 3-4 neu­ro­tox­i­c­i­ty seen in three in­di­vid­u­als among 22 in the dose lev­el 1 group who were evalu­able for safe­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.